Nefazodone is a serotonin antagonist and reuptake inhibitor (SARI) that has been withdrawn from the market in many developed countries (including Australia, Canada, Germany, Italy, New Zealand, Spain, the U.K., etc.), although it is still marketed in Greece and the U.S.A. On top of its SARI activity it also serves as a noradrenaline reuptake inhibitor.